LDL earns its “bad cholesterol” reputation because its particles physically enter artery walls, get trapped there, undergo chemical changes, and set off a chain of inflammatory events that gradually build into plaques. Those plaques narrow arteries, stiffen vessel walls, and can rupture suddenly to cause heart attacks and strokes. The damage is not a single event but a slow, self-reinforcing cascade that often begins decades before symptoms appear, and the details of how it unfolds explain a lot about why some people with “normal” cholesterol still develop heart disease.
How LDL Gets Trapped Inside Artery Walls
The inner lining of your arteries, called the endothelium, is not a perfect seal. LDL particles are small enough to slip between or through endothelial cells and enter the tissue underneath, known as the intima. In healthy arteries at low LDL concentrations, most of these particles pass through and exit out the other side. The trouble starts when LDL levels are high or the endothelium is stressed by factors like high blood pressure or smoking: more particles enter, and they start getting stuck.
What traps them is a mesh of molecules called proteoglycans. These molecules carry negatively charged sugar chains, and a specific protein on the surface of each LDL particle, apolipoprotein B-100, has positively charged segments that latch onto those chains like Velcro. Once bound, the LDL particle’s transit time in the artery wall increases dramatically.1Atherosclerosis. Why Is LDL Bad? How It Damages Your Arteries That extended residence time is the critical first step. The particle is no longer just passing through; it is parked in a place where it will undergo changes that make everything worse.2Medicine in Novel Technology and Devices. Interaction of arterial proteoglycans with low density lipoproteins (LDLs): From theory to promising therapeutic approaches
What Happens When Trapped LDL Oxidizes
A freshly trapped LDL particle is not especially dangerous on its own. The body’s normal cleanup systems can handle some amount of it. But once stuck in the artery wall, LDL is exposed to enzymes and reactive oxygen species that chemically alter it through a process broadly called oxidation. The result is oxidized LDL, or oxLDL, and this modified form is where real trouble begins.3PubMed Central. Mechanistic Insights into the Oxidized Low-Density Lipoprotein-Induced Atherosclerosis
Oxidized LDL behaves very differently from the native particle. Your body’s immune system recognizes it as something foreign and harmful. Immune cells, particularly macrophages, are recruited to the site to deal with the threat. But here is the problem: the normal system for taking up LDL is tightly regulated. Cells have receptors that sense how much cholesterol they already contain and shut down uptake when they have enough. Oxidized LDL bypasses that safety mechanism entirely. It enters macrophages through a different set of receptors, called scavenger receptors, that have no off switch.4PubMed Central. Oxidized LDL phagocytosis during foam cell formation in atherosclerotic plaques relies on a PLD2-CD36 functional interdependence
Foam Cells and How Plaques Begin
Because scavenger receptors never tell the macrophage to stop eating, the cell keeps gorging on oxidized LDL. It fills up with so much cholesterol that under a microscope it looks bubbly and swollen, which is why researchers call it a foam cell. Foam cell formation is widely recognized as the first real step in building an atherosclerotic plaque.5PubMed Central. Modification macrophage to foam cells in atherosclerosis disease: some factors stimulate or inhibit this process
Foam cells do not just sit there quietly. They release inflammatory signals that call in more immune cells, which encounter more oxidized LDL, become more foam cells, and amplify the cycle. Many of these overloaded cells eventually die, spilling their cholesterol cargo into the surrounding tissue. Over time, this creates a growing pool of lipids, dead cells, and debris at the core of the developing plaque. This necrotic core is the soft, unstable center that will later pose the greatest danger.
Cholesterol Crystals and the Inflammation Loop
As cholesterol accumulates in the growing plaque, some of it solidifies into microscopic crystals. These crystals are not just passive bystanders. They physically damage the internal compartments of macrophages, particularly their lysosomes, the cellular recycling centers. When a lysosome is punctured by a sharp crystal, its contents leak into the rest of the cell and trigger a powerful inflammatory alarm system called the NLRP3 inflammasome.6European Heart Journal. Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque
Activation of this inflammasome drives the production of a potent inflammatory molecule, interleukin-1β, which in turn raises C-reactive protein and promotes further immune cell recruitment. Recent research has uncovered additional ways cholesterol crystals activate this same inflammasome, including through signaling pathways related to cholesterol movement within cells and through activation of the complement system, a branch of the immune system normally used to fight infections.7PubMed. Cholesterol Crystals as Triggers of NLRP3 Inflammasome Activation in Atherosclerosis The result is the same: sustained, low-grade inflammation that destabilizes the plaque from within.
The Fibrous Cap and What Makes Plaques Rupture
The body does not simply let a plaque grow unchecked without any attempt at containment. Smooth muscle cells from the artery wall migrate into the plaque and lay down a layer of collagen and other structural proteins over the necrotic core. This protective shell is called the fibrous cap, and it separates the plaque’s dangerous contents from the flowing blood.8PubMed Central. Mechanisms of fibrous cap formation in atherosclerosis The fibrous cap’s collagen gives it tensile strength, much like collagen strengthens skin and tendons.9JCI Insight. Collagenases and cracks in the plaque
A thick, stable fibrous cap can keep a plaque contained for years or even a lifetime. The problem is that the ongoing inflammation inside the plaque actively works to undermine this protection. Macrophages and other inflammatory cells produce enzymes called matrix metalloproteinases that chew through collagen, thinning the cap over time.10PubMed. Role of inflammation and metalloproteinases in plaque disruption and thrombosis Those same inflammatory cells also inhibit the survival and function of the smooth muscle cells responsible for building and maintaining the cap.11Cardiovascular Research. Fibrous cap formation or destruction — the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation So the cap is being weakened from both directions: less material going in, and more being broken down.
When the cap gets thin enough, it can crack. The moment it does, the thrombogenic contents of the necrotic core contact the bloodstream, and the blood-clotting system activates immediately. A clot forms on the spot and can partially or fully block the artery. If this happens in a coronary artery, the result is a heart attack. If it happens in an artery feeding the brain, it causes a stroke. Most fatal heart attacks result from plaque rupture rather than from gradual narrowing of the artery.
LDL’s Direct Damage to Artery Function
Beyond building plaques, oxidized LDL also impairs the basic function of artery walls in a way that makes cardiovascular problems worse. Healthy arteries relax and widen in response to increased blood flow, a process that depends on the endothelium producing nitric oxide. Nitric oxide is the signal that tells the smooth muscle surrounding the artery to relax. Oxidized LDL specifically blocks this nitric oxide pathway without affecting other dilation mechanisms, meaning arteries exposed to it become stiff and less responsive to changing blood flow demands.12PubMed. oxLDL specifically impairs endothelium-dependent, NO-mediated dilation of coronary arterioles
The mechanism involves oxidized LDL ramping up production of an enzyme called arginase in the artery wall. Arginase competes for the same raw material that the nitric oxide-producing enzyme needs, essentially starving the system of its key ingredient. When researchers blocked arginase activity in lab studies, the nitric oxide pathway was restored and arteries relaxed normally again.13PubMed Central. Oxidized low-density lipoprotein inhibits nitric oxide-mediated coronary arteriolar dilation by up-regulating endothelial arginase I This endothelial dysfunction is not just a consequence of atherosclerosis; it also accelerates it, because an artery that cannot relax properly experiences greater mechanical stress, which in turn promotes more LDL entry.
Not All LDL Particles Are Equally Dangerous
A standard cholesterol test reports a single number for LDL cholesterol, but LDL is actually a family of particles that vary in size and density. The smallest, densest LDL particles appear to be the most harmful. They slip into artery walls more easily because of their small size, they circulate longer in the blood because the liver’s cleanup receptors have a harder time grabbing them, and they are more susceptible to oxidation.14PubMed Central. Small dense LDL: An underestimated driver of atherosclerosis Each of those characteristics lines up with a step in the damage cascade described above: easier entry, longer exposure time, faster conversion to the oxidized form that triggers foam cell formation.
This matters clinically because two people can have the same LDL cholesterol number on a blood test but very different levels of risk. Someone whose LDL is dominated by large, buoyant particles may carry less danger per milligram of cholesterol than someone with the same reading who is carrying mostly small, dense particles.15PubMed Central. The effects of fat consumption on low-density lipoprotein particle size in healthy individuals: a narrative review High triglycerides are a major driver of the shift toward small dense LDL. In patients hospitalized for acute coronary events, triglyceride levels correlated strongly with the concentration of small dense LDL particles.16PubMed Central. Triglyceride and Small Dense LDL-Cholesterol in Patients with Acute Coronary Syndrome This is one reason that metabolic conditions like insulin resistance and type 2 diabetes raise heart disease risk even when total LDL cholesterol looks unremarkable.
Why Some Experts Prefer ApoB Over LDL Cholesterol
Every LDL particle has exactly one copy of apolipoprotein B (apoB) on its surface. That means measuring apoB in the blood tells you the actual number of atherogenic particles floating around, while the standard LDL cholesterol test tells you only the total mass of cholesterol riding inside those particles. Two people with identical LDL cholesterol levels can have very different particle counts, and the person with more particles tends to have more risk.
The evidence backing apoB as a superior risk marker is increasingly hard to ignore. In a comprehensive review, apoB outperformed LDL cholesterol in every study that compared the two directly.17PubMed. ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk A separate large study found that the portion of apoB not accounted for by LDL cholesterol alone carried its own dose-dependent risk for heart attack and cardiovascular disease in both women and men, meaning apoB captures risk that the standard test misses entirely.18PubMed. Excess Apolipoprotein B and Cardiovascular Risk in Women and Men
Multiple expert groups have concluded that apoB is a more accurate, more precise, and more standardized measurement than LDL cholesterol, and it can be done cheaply on widely available equipment.19PubMed Central. Standardization of Apolipoprotein B, LDL-Cholesterol, and Non-HDL-Cholesterol So why is it not the default test? Partly inertia. LDL cholesterol has been the clinical standard for decades, treatment guidelines are built around it, and changing that infrastructure takes time. If your doctor offers apoB testing, it can give you a sharper picture of your actual risk, particularly if you have normal LDL cholesterol but elevated triglycerides or metabolic syndrome.
Genetic Evidence That LDL Causes the Damage
A persistent question in medicine was whether high LDL merely accompanies heart disease or actually causes it. The answer, confirmed through a line of research called Mendelian randomization, is that LDL is causal. The logic is elegant: some people are born with gene variants that naturally give them slightly lower or higher LDL levels for their entire lives. Because these variants are randomly distributed at conception, they serve as a natural experiment free from the confounding factors that plague observational studies.
A meta-analysis of over 300,000 participants found that people genetically programmed for lifelong lower LDL had about a 55% reduction in coronary heart disease risk for each unit of LDL lowered, a much larger effect than what you see from starting a statin in middle age for the same LDL reduction.20PubMed. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis That gap makes sense: the genetic group had lower LDL from birth, accumulating decades less arterial damage than someone who starts treatment at fifty. A separate study of a common variant in the LDL receptor gene found that carriers with genetically lower LDL had less coronary artery disease, and structural modeling confirmed the protective effect disappeared once you statistically accounted for the LDL difference, proving the protection came through the LDL pathway itself.21PLOS ONE. Lifelong Reduction of LDL-Cholesterol Related to a Common Variant in the LDL-Receptor Gene Decreases the Risk of Coronary Artery Disease—A Mendelian Randomisation Study
The pattern is remarkably consistent across different genes: nearly every variant that raises LDL also raises coronary artery disease risk, and nearly every variant that lowers it provides protection.22European Heart Journal. Mendelian randomization studies in coronary artery disease This consistency across dozens of independent genetic pathways makes the case that LDL is a cause, not just a bystander, about as strong as causal evidence gets outside of a randomized trial.
Can Plaques Actually Shrink?
Given that the damage process described above unfolds over decades, a natural question is whether it can be reversed. The answer is a qualified yes. Imaging studies using intravascular ultrasound have shown that aggressive cholesterol-lowering therapy can reduce plaque volume, thicken the protective fibrous cap, shrink the lipid core, and decrease the infiltration of inflammatory cells.23PubMed Central. The Goal of Achieving Atherosclerotic Plaque Regression with Lipid-Lowering Therapy: Insights from IVUS Trials In other words, treatment does not just slow the process but can partially undo it.
More recent evidence using additional imaging techniques confirms these findings: intensive lipid-lowering therapy induces measurable plaque regression and improves plaque composition, shifting it from the vulnerable, rupture-prone type toward a more stable structure.24PubMed. The clinical relevance of the reversal of coronary atherosclerotic plaque The caveat is that regression is partial, not total. A heavily calcified or scarred plaque will not disappear entirely. And the degree of regression depends heavily on how low LDL levels are driven and for how long. Still, the fact that the process is at least partially reversible reinforces the point that LDL concentration is not just a risk marker you monitor but an active driver of disease you can meaningfully intervene on.
How the Liver Clears LDL and What Can Go Wrong
Most LDL removal from the blood happens in the liver, which pulls particles out of circulation using LDL receptors on its surface. The more receptors the liver displays, the faster LDL is cleared and the lower your blood levels stay. This is actually the mechanism behind statins: by blocking cholesterol production inside liver cells, statins force the liver to put out more LDL receptors to grab cholesterol from the blood instead.
A protein called PCSK9 works against this process. It binds to LDL receptors and tags them for destruction, reducing the liver’s ability to clear LDL. Conditions that increase PCSK9 production, like fatty liver disease, can raise LDL levels by degrading receptors faster than the liver can replace them.25Journal of Biological Chemistry. Diet-induced hepatic steatosis increases circulating PCSK9 and decreases hepatic LDL receptor expression in a PCSK9-dependent manner This is one of the reasons that fatty liver, increasingly common in people with metabolic syndrome, tends to worsen cholesterol profiles. Newer injectable drugs called PCSK9 inhibitors work by blocking this protein, allowing the liver to keep more receptors active and pull more LDL out of the blood.
LDL in Evolutionary Context
An interesting perspective on why LDL causes so much trouble comes from evolutionary biology. LDL is not inherently toxic. It is a vital transport vehicle that delivers cholesterol and fats to cells throughout the body for essential functions like building cell membranes and making hormones. The problem is one of concentration. Modern human LDL levels are far above what our physiology evolved to handle. Studies of contemporary hunter-gatherer populations, which offer the closest approximation to ancestral human metabolism, consistently find total cholesterol levels below 150 mg/dL, a number that most Western adults would consider unusually low.26PubMed. Humans, lipids and evolution
At those low concentrations, the rate of LDL entering artery walls stays below the tissue’s capacity to clear it out. The retention-oxidation-inflammation cascade described in this article barely gets started. It is only when concentrations rise above what the arterial cleanup system can handle that the retention mechanism kicks into gear and disease begins to develop. In that sense, atherosclerosis is not a failure of the body’s design but a mismatch between our ancient biology and the lipid loads produced by modern diets and sedentary lifestyles.
How Hormonal Changes Shift LDL Risk
LDL levels are not static across a person’s lifetime. One of the most striking shifts occurs in women after menopause. Estrogen helps the liver clear LDL from the blood, and when estrogen levels drop at menopause, LDL concentrations tend to rise. Research on postmenopausal estrogen replacement found that oral estrogen reduced LDL cholesterol by roughly 14 to 19 percent, largely because it increased the rate at which the liver broke down LDL particles by about a third.27New England Journal of Medicine. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
This hormonal influence helps explain why women’s heart disease risk tends to converge with men’s after menopause. It also underscores that the damage LDL causes is fundamentally dose- and time-dependent. A woman who lived most of her adult life with estrogen-supported LDL clearance accumulated less arterial damage by age fifty than a man with the same genetic cholesterol tendencies. Once estrogen drops, however, the rate of LDL entry into artery walls may begin outpacing clearance, and the cascade accelerates. Hormone replacement therapy’s effect on LDL is real, but its net cardiovascular impact depends on many other factors, including when treatment starts relative to menopause, which is why the decision is individualized rather than universal.